Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 02, 2024 10:47pm
232 Views
Post# 35808100

RE:RE:RE:RE:RE:Early warrant exercise

RE:RE:RE:RE:RE:Early warrant exercise I wouldn't get too hung up on these warrants.  The math makes sense to me.

Let's put it this way ... If you could get 100% (or a high percentage) of the warrants exercised in this 1 month window, you could bring in more money than waiting until July (summer doldrums) to exercise.

Remember, there are 6.5MM warrants looking to do the same ...

So, at what price would you need to convert your $1.00 warrants into shares and sell them all at market to still make money?  Remember ... 6.5MM warrants could be doing the same thing while buy/sell volume may be low.

Same question ... what price would you need to convert your $1.50 warrants into shares and sell them all at market to still make money?  Remember there are 6.5MM warrants all doing the same thing.

---------------

Why would ATE offer this opportunity at $1.00?  Because any money added to the bank now would be better than uncertainty later in 2024.  What if the markets turn ugly in 2024?  There is a lot of bad in the world and it's only going to get uglier ... including war, US politics and mortgage renewals for many.

If you can convert warrants to cash now - you are buying time before you need to further go to market.  You could also buy time during some partnership negotiations too.  That could be the difference between going to the TSX or going to the NASDAQ in an offering.  IMO.

---------------

From what I recall - Insiders don't hold these warrants.  If I recall correctly, insiders agreed to drop their warrants in order to reprice the rest of the warrants.  Something like that - to avoid any concern of playing to the insiders.  Anyone know if I have that right ?
<< Previous
Bullboard Posts
Next >>